Hipogonadotropik hipogonadizm nedenleri Hipotalamik nedenler * GnRH noronlarinin migrasyonu ile ilgili Kal-1 gen defekti FGF1 gen defekti Prokineticin
2 gen defekti * GnRH sekresyon bozuklugu * GnRH reseptor gen * Leptin / leptin reseptor * GPR 54 gen mutasyonu * Kisspeptin gen mutasyonu Hipofizer nedenleri * Hipofizin gelisim bozukluguna bagli * [beta]BLH, pFSH mutasyonlari * LH / FSH reseptor gen mutasyonlari * Hipotalamo-Hipofizer tumor (Kraniofaringioma vs.
Mutations in the prokineticin
2 peptide (PROK2) and its transmembrane domain type 2 receptor (PROKR2) are newly identified molecular culprits in autosomal KS.
2 is a recently discovered signaling molecule that occurs naturally in the part of the brain that helps control hunger.
Topics include the physiological role of vasopressin and oxytocin during the pathophysiology of sepsis, prokineticin
1 and 2, mass spectrometry methods, somatostatin expression during inflammation, and neuropeptide hormone dysregulation in PCOS.
Kinexis is in pre-clinical trials with its Prokineticin
protein, a potential treatment for insomnia, gut motility problems and other disorders connected with the circadian rhythm.
lt; < Family Receptor Type GPCRs < < GPR GPR120 < < Protease Activ- PAR4 < < Lysophospholip- S1P2 (Edg5) < < Urotensin rUT < < Serotonin 5-HT3A < < Glucagon GLP-2 < < Prokineticin
PKR2 < < GPR GPR91 < < Glucagon Secretin < < Dopamine D2L < < Purinergic P2Y11 < < GPR GPR1 < < NeuropeptideFF NPFF1 Ion channels < < Voltage gated Kv1.
Kinexis and Merck have been collaborating during the past year on the biologic target validation of a prokineticin receptor in central nervous system (CNS) indications.
Achieving this milestone demonstrates the ability of Kinexis to work effectively with our network of collaborators to validate the prokineticin pathway for drug discovery and development," said Patricia L.
GPR54 and its ligand metastin, prokineticin
2 and its receptor, and the FGFR1 signaling pathway are all critical elements for GnRH neuron integrity in humans discovered using these approaches.
Kinexis' collaboration with Merck involves biologic target validation and small molecule screening of a prokineticin receptor in central nervous system (CNS) indications.
Kinexis is a young company built around the newly discovered prokineticin ligand/receptor pairs and their related biology.